Imidazo[4,5-C]quinoline derivatives as LRRK2 inhibitors

US11312713B2 · kind B2 · utility

Assignee

• PFIZER INC. · US

Inventors

• Michael Aaron Brodney · East Lyme, US
• Thomas Allen Chappie · Old Lyme, US
• Jinshan Chen · Madison, US
• Jotham Wadsworth Coe · Niantic, US
• Karen Coffman · Pawcatuck, US
• Paul Galatsis · Newton, US
• Michelle Renee Garnsey · Medford, US
• Christopher John Helal · Mystic, US
• Jaclyn Louise Henderson · Cambridge, US
• Bethany Lyn Kormos · Somerville, US
• Ravi G. Kurumbail · East Lyme, US
• Luis Angel Martinez-Alsina · Gales Ferry, US
• Martin Youngjin Pettersson · Waterford, US
• Matthew Richard Reese · Mystic, US
• COLIN RICHARD ROSE · Quaker Hill, US
• Antonia Friederike Stepan · Providence, US
• Patrick Robert Verhoest · Newton, US
• Travis T. Wager · Brookline, US
• Joseph Scott Warmus · Ann Arbor, US
• Yuan Zhang · Edmond, US

Key dates

• Filing date: Mar 6, 2018
• Grant date: Apr 26, 2022
• Expiry date: Apr 14, 2038

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D519/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides novel imidazo[4,5-c]quinoline derivatives of Formula (I), and the pharmaceutically acceptable salts thereof I wherein R1, R2 and R3 are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of Formula I and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.